OneSource and BRL ink technology licensing agreement to deliver high-concentration biologics subcutaneously

Revolutionary technology will further boost OneSource’s scientific services offerings

GSK and Flagship partner to discover novel medicines and vaccines

GSK and Flagship to jointly fund up to $150 million upfront

Merck Life Science inks MoU with ICAR-CIFT, Kochi for research in fishing process

Bayer announces positive topline results for Nubeqa from Phase III trial in men with mHSPC

Phase III ARANOTE trial met primary endpoint, significantly increasing radiological progression-free survival (rPFS) with NUBEQA plus androgen deprivation therapy (ADT) compared to placebo plus ADT

Lilly to acquire Morphic to improve outcomes for patients with inflammatory bowel disease

Acquisition to expand Lilly's immunology pipeline with oral integrin therapies

Surfix Diagnostics, NKI and CRCbioscreen join forces to validate biomarkers for colorectal cancer screening

Globally, colorectal cancer impacts 1.9 million people each year, standing as a leading cause of cancer mortality

Olink announces receipt of CMA clearance for proposed acquisition by Thermo Fisher

Shares and American Depositary Shares of Olink for $26.00 per Share

GSK and CureVac restructure collaboration into new licensing agreement

CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced

USDA approves Merck Animal Health’s NOBIVAC NXT canine flu H3N2

Innovative technology represents a breakthrough scientific achievement for highly contagious respiratory disease

Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide

Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024